Diamond Biotechnology Co

Diamond Biotechnology Co Current Assets

The Current Assets of Diamond Biotechnology Co (6815.TWO) as of Oct 22, 2026 is 101.66 M TWD. In the previous year, Current Assets was 779.41 M TWD — a change of -86.96% (lower).

Current Assets

101.66 MTWD

YoY

-86.96%

Last updated:

Current Assets of Diamond Biotechnology Co is 2025 101.66 M TWD. Current Assets of Diamond Biotechnology Co was 2024 779.41 M TWD. It decreases by -86.96% lower compared to the previous year.

The Diamond Biotechnology Co Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
158.59 M TWD
Jan 1, 2019
246.54 M TWD
Jan 1, 2020
245.56 M TWD
Jan 1, 2021
355.49 M TWD
Jan 1, 2022
369.22 M TWD
Jan 1, 2023
397.44 M TWD
Jan 1, 2024
779.41 M TWD
Jan 1, 2025
101.66 M TWD
The Diamond Biotechnology Co Current Assets history
YEARCurrent AssetsYoY
101.66 MTWD-86.96%
779.41 MTWD+96.11%
397.44 MTWD+7.64%
369.22 MTWD+3.86%
355.49 MTWD+44.77%
245.56 MTWD-0.40%
246.54 MTWD+55.45%
158.59 MTWD+16.30%
136.37 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Diamond Biotechnology Co Stock analysis

What does Diamond Biotechnology Co do? Diamond Biotechnology Co., Ltd. generates revenue through the research, development, manufacturing, and sale of skincare products and medical equipment. The company's skincare products include facial masks, lotions, creams, and essences, primarily used for facial skin care and cleaning. Medical equipment offerings consist of wires, sonic wave devices, radio wave devices, frozen fat reduction equipment, and micro plastic surgery consumables such as botulinum and collagen injections, targeting skin wrinkle and sagging improvement. The firm also provides medical equipment leasing services and medical beauty management consulting services to its clients. The primary customers for skincare products are individuals seeking facial care solutions, while medical equipment and consumables are purchased by clinics and medical facilities specializing in aesthetic procedures. The company serves both domestic and overseas markets, with its medical beauty management consulting services catering to businesses in the aesthetic industry. Diamond Biotechnology focuses on direct sales of its products and services, leveraging its domestic market presence and expanding into international territories to drive revenue growth. Revenue streams are diversified across product categories and service offerings, with skincare products accounting for a significant portion of sales alongside medical equipment and consumables. The company's medical equipment leasing services provide recurring income, while consulting services support long-term client relationships. By maintaining a dual focus on consumer skincare and professional medical aesthetics, Diamond Biotechnology ensures steady demand across its product lines and service segments. Diamond Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Diamond Biotechnology Co stock

Current Assets of Diamond Biotechnology Co is 101.66 M TWD in 2025.

Current Assets of Diamond Biotechnology Co changed from 779.41 M TWD to 101.66 M TWD, representing a -86.96% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Diamond Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Diamond Biotechnology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Diamond Biotechnology Co

All Key Metrics — Diamond Biotechnology Co